Unknown

Dataset Information

0

Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.


ABSTRACT: We previously described adoptive immunotherapy (AIT) with cytotoxic T lymphocytes (CTLs) stimulated by the mucin 1 (MUC1)-expressing human pancreatic cancer cell line YPK-1 (MUC1-CTLs) and demonstrated that MUC1-CTLs might prevent liver metastasis. In the present study, we combined gemcitabine (GEM) and AIT for the treatment of pancreatic cancer.A total of 43 patients who underwent radical pancreatectomy received treatment with MUC1-CTLs and GEM. After surgery, MUC1-CTLs were induced and administered intravenously 3 times, and GEM administered according to the standard regimen for 6 months. The patients whose relative dose intensity of GEM was 50% or more and who received 2 or more MUC1-CTL treatments were used as the adequate treatment group (n = 21).In the adequate treatment group, disease-free survival was 15.8 months, and overall survival was 24.7 months. Liver metastasis was found only in 7 patients (33%), and local recurrence occurred in 4 patients (19%). The independent prognostic factor of long-term disease-free survival on multivariate analysis was the average number of CTLs administered (P = 0.0133).The combination therapy with AIT and GEM prevented liver metastasis and local recurrence. Moreover, the disease free-survival was improved in patients who received sufficient CTLs.

SUBMITTER: Matsui H 

PROVIDER: S-EPMC5555975 | biostudies-other | 2017 Sep

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC3176241 | biostudies-literature
| S-EPMC6296745 | biostudies-literature
| S-EPMC7255981 | biostudies-literature
| S-EPMC4074851 | biostudies-literature
| S-EPMC8437098 | biostudies-literature
| S-EPMC5740086 | biostudies-literature
| S-EPMC6311014 | biostudies-literature
| S-EPMC6345263 | biostudies-literature
| S-EPMC4209539 | biostudies-literature
| S-EPMC9437831 | biostudies-literature